Board of Directors

Mr. GP Singh, A global pharma CEO with 25+ years’ experience of successfully establishing and operating complex businesses. Before co-founding SHINKEI he has managed multiple types of pharmaceutical businesses across various geographies during his tenure at Jubilant Pharma as Global CEO. Prior to Jubilant, Singh had served as President of Sun Pharmaceuticals, US and as CEO of Caraco Pharma contributing to the growth of US businesses. GP has expertise in establishing world-class commercial, manufacturing and development organizations and lead them on growth path through inorganic and organic growth strategies.

Suresh Borsadia is a senior-level executive with more than 25 years’ experience in the pharmaceutical/drug delivery industry. He has a demonstrated track record of value creation and successful deal closings, supplemented with a background and experience in R&D. Prior to co-founding SHINKEI Therapeutics, he set-up Sun Pharma’s thin film technology capabilities, including commercial manufacturing. He co-founded Abeille after working for Lavipharm, TheraTech Inc (Teva) and Bertek Inc (Mylan) where he played a key role in R&D, in-licensing and out-licensing activities.

Ram is a seasoned pharmaceutical executive and entrepreneur with over 35 years of experience. His areas of expertise include finance, accounting, tax, supply chain, and product strategy. Ram began his career as the controller of Duramed Pharmaceuticals in Long Island, New York. He was the founder and Chief Operating Officer of Cadista Pharmaceuticals, now a division of Jubilant Life Sciences of India. Ram served, most recently as the executive vice president of Epic Pharmaceuticals, where he led the sale process of the company to Humanwell Healthcare of China. Ram is active in biotech and specialty pharma venture capital. He was an initial investor and board member of InnoPharma, which was later acquired by Pfizer. Ram received BS. in Chemistry from the University of Kerala, India and is a CPA